Medtronic plc (NYSE:MDT – Get Free Report) has been given an average rating of “Hold” by the sixteen research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, eight have given a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $95.36.
MDT has been the topic of a number of analyst reports. Piper Sandler lifted their target price on shares of Medtronic from $85.00 to $90.00 and gave the company a “neutral” rating in a research note on Wednesday, August 21st. Barclays lifted their target price on Medtronic from $104.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, August 22nd. Citigroup upped their price target on Medtronic from $85.00 to $92.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 1st. Oppenheimer lifted their price objective on shares of Medtronic from $92.00 to $94.00 and gave the company a “market perform” rating in a research report on Wednesday, August 21st. Finally, Wells Fargo & Company upped their target price on shares of Medtronic from $105.00 to $106.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st.
View Our Latest Research Report on Medtronic
Institutional Trading of Medtronic
Medtronic Stock Performance
Shares of MDT opened at $91.05 on Tuesday. Medtronic has a 52 week low of $68.84 and a 52 week high of $92.25. The company has a quick ratio of 1.61, a current ratio of 2.13 and a debt-to-equity ratio of 0.55. The stock has a market cap of $116.75 billion, a price-to-earnings ratio of 33.11, a PEG ratio of 2.53 and a beta of 0.84. The business has a 50-day simple moving average of $88.65 and a two-hundred day simple moving average of $83.63.
Medtronic (NYSE:MDT – Get Free Report) last released its earnings results on Tuesday, August 20th. The medical technology company reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. The company had revenue of $7.97 billion for the quarter, compared to analysts’ expectations of $7.90 billion. Medtronic had a net margin of 12.06% and a return on equity of 13.68%. The firm’s revenue was up 3.4% compared to the same quarter last year. During the same quarter last year, the business earned $1.20 EPS. On average, analysts expect that Medtronic will post 5.44 EPS for the current year.
Medtronic Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Friday, October 11th. Stockholders of record on Friday, September 27th were issued a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 3.08%. The ex-dividend date was Friday, September 27th. Medtronic’s dividend payout ratio (DPR) is 101.82%.
Medtronic Company Profile
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Recommended Stories
- Five stocks we like better than Medtronic
- Compound Interest and Why It Matters When Investing
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.